MA38138A1 - Dérivés inédits de quinolone - Google Patents

Dérivés inédits de quinolone

Info

Publication number
MA38138A1
MA38138A1 MA38138A MA38138A MA38138A1 MA 38138 A1 MA38138 A1 MA 38138A1 MA 38138 A MA38138 A MA 38138A MA 38138 A MA38138 A MA 38138A MA 38138 A1 MA38138 A1 MA 38138A1
Authority
MA
Morocco
Prior art keywords
quinolone
new derivatives
preparation
compounds
formula
Prior art date
Application number
MA38138A
Other languages
English (en)
Inventor
Ranjit C Desai
Vrajesh Pandya
Pankaj R Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MA38138A1 publication Critical patent/MA38138A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés inédits de formule générale (i), leurs formes tautomères, leurs stéréo-isomères, leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques en contenant, leurs procédés de préparation, l'utilisation desdits composés en médecine et les intermédiaires impliqués dans leur préparation. [formule à insérer ici]
MA38138A 2012-12-24 2015-05-29 Dérivés inédits de quinolone MA38138A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3600MU2012 2012-12-24
PCT/IN2013/000796 WO2014102818A1 (fr) 2012-12-24 2013-12-23 Dérivés inédits de quinolone

Publications (1)

Publication Number Publication Date
MA38138A1 true MA38138A1 (fr) 2016-11-30

Family

ID=54148255

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38138A MA38138A1 (fr) 2012-12-24 2015-05-29 Dérivés inédits de quinolone

Country Status (26)

Country Link
US (1) US9394300B2 (fr)
EP (1) EP2935221B1 (fr)
JP (1) JP6026013B2 (fr)
KR (1) KR101733901B1 (fr)
CN (1) CN104903295B (fr)
AP (1) AP2015008502A0 (fr)
AR (1) AR094300A1 (fr)
AU (1) AU2013368843B2 (fr)
BR (1) BR112015014222B1 (fr)
CA (1) CA2894636C (fr)
CL (1) CL2015001802A1 (fr)
EA (1) EA028402B1 (fr)
ES (1) ES2660288T3 (fr)
IL (1) IL239109B (fr)
JO (1) JO3781B1 (fr)
MA (1) MA38138A1 (fr)
MX (1) MX373392B (fr)
MY (1) MY175854A (fr)
NZ (1) NZ708605A (fr)
PH (1) PH12015501452B1 (fr)
SG (1) SG11201504458XA (fr)
TR (1) TR201802305T4 (fr)
TW (1) TWI598339B (fr)
UA (1) UA117122C2 (fr)
WO (1) WO2014102818A1 (fr)
ZA (1) ZA201503814B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6506390B2 (ja) * 2014-09-02 2019-04-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． キノリノン系化合物及びその薬物への使用
WO2016045125A1 (fr) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibiteurs de la prolyl hydroxylase du hif
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
CA3062972C (fr) * 2017-05-09 2021-09-14 Kind Pharmaceutical Derives d'indolizine et leur application en medecine
PL3759109T3 (pl) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Podstawione związki pirolizyny jako inhibitory replikacji hbv
TW202200547A (zh) * 2020-03-13 2022-01-01 印度商卡地拉保健有限公司 喹啉酮化合物的新穎鹽類
WO2021186356A1 (fr) * 2020-03-17 2021-09-23 Cadila Healthcare Limited Formulation comprenant des inhibiteurs de hif prolyl hydroxylase
WO2021216530A1 (fr) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Traitement d'infections virales, d'une lésion d'organe et d'états apparentés à l'aide d'un inhibiteur de hif prolyl hydroxylase ou d'un stabilisateur hif-alpha
WO2021240454A1 (fr) * 2020-05-29 2021-12-02 Cadila Healthcare Limited Traitement du psoriasis et de maladies inflammatoires de la peau
WO2021245533A1 (fr) * 2020-06-01 2021-12-09 Cadila Healthcare Limited Traitement de la maladie inflammatoire chronique de l'intestin
WO2022150623A1 (fr) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Composés et composition pour traiter l'anémie
CN116997331A (zh) * 2021-03-19 2023-11-03 兹杜斯生命科学有限公司 固体形式的喹诺酮化合物及其制备方法
WO2022195532A1 (fr) 2021-03-19 2022-09-22 Zydus Lifesciences Ltd. Traitement de la drépanocytose
WO2022238745A1 (fr) * 2021-05-14 2022-11-17 Zydus Lifesciences Limited Composition pharmaceutique topique d'inhibiteurs de hif prolyl hydroxylase
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
CN113549011B (zh) * 2021-08-10 2023-05-09 广东东阳光药业有限公司 德度司他的共晶或盐及其制备方法和用途
US20240408022A1 (en) * 2021-09-20 2024-12-12 Zydus Lifesciences Limited Desidustat particles and compositions thereof
US20250387385A1 (en) * 2022-06-24 2025-12-25 Zydus Lifesciences Limited Treatment for glomerular diseases
EP4565233A1 (fr) * 2022-08-01 2025-06-11 Zydus Lifesciences Limited Traitement de l'anémie aplasique (aa)
AU2024366956A1 (en) 2023-10-24 2026-04-09 Kind Pharmaceutical Long-acting oral pharmaceutical comprising hypoxia-inducible factor prolyl hydroxylase inhibitor and use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
CA2528232C (fr) 2003-06-06 2010-05-25 Fibrogen, Inc. Nouveaux composes heteroaryles contenant de l'azote et leur utilisation pour augmenter l'erythropoietine endogene
WO2006094292A2 (fr) * 2005-03-02 2006-09-08 Fibrogen, Inc. Nouveaux composes a base de thienopyridine et procedes d'utilisation correspondants
WO2007038571A2 (fr) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Antagonistes de la prolyl-hydroxylase
JP5202327B2 (ja) * 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
CN103497184A (zh) * 2006-04-04 2014-01-08 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
WO2007136990A2 (fr) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Inhibiteurs de prolyl hydroxylase
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2142509B1 (fr) * 2007-04-18 2013-12-04 Amgen, Inc Quinolones et azaquinolones inhibant la prolyl hydroxylase
CA2683758A1 (fr) * 2007-04-18 2008-10-30 Merck & Co., Inc. Nouveaux composes de type 1,8-naphthyridine
US8097620B2 (en) * 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
ES2389063T3 (es) * 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
WO2008138060A1 (fr) * 2007-05-16 2008-11-20 Cowper Norman T Système et procédé de maximisation de la concentration en matières solides d'une boue pompée à travers un pipeline
WO2009070644A1 (fr) * 2007-11-30 2009-06-04 Smithkline Beecham Corporation Inhibiteurs de prolyl hydroxylases
JP2011513222A (ja) * 2008-02-25 2011-04-28 メルク・シャープ・エンド・ドーム・コーポレイション テトラヒドロチエノピリジン
CA2714111A1 (fr) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Pyridones a tetrahydro-1h-pyrrolo fusionne
CN101951777A (zh) * 2008-02-25 2011-01-19 默沙东公司 四氢呋喃并吡啶酮
JP2011525924A (ja) * 2008-06-25 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
SI2455381T1 (sl) 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
AR077892A1 (es) * 2009-08-20 2011-09-28 Vifor Int Ag Quinolinas antagonistas de la hepcidina
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
WO2013043621A1 (fr) 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Pyrimidines substituées
JPWO2013115265A1 (ja) * 2012-01-31 2015-05-11 富山化学工業株式会社 抗ｈｉｖ活性を有する複素環化合物

Also Published As

Publication number Publication date
PH12015501452B1 (en) 2018-06-06
MX373392B (es) 2020-04-20
AR094300A1 (es) 2015-07-22
IL239109A0 (en) 2015-07-30
CN104903295B (zh) 2017-09-01
MX2015008233A (es) 2015-09-29
BR112015014222A2 (pt) 2017-07-11
AU2013368843A1 (en) 2015-06-18
KR101733901B1 (ko) 2017-05-08
AU2013368843B2 (en) 2016-02-25
ZA201503814B (en) 2016-05-25
CN104903295A (zh) 2015-09-09
JO3781B1 (ar) 2021-01-31
HK1211022A1 (en) 2016-05-13
EA201591195A1 (ru) 2015-10-30
US20150299193A1 (en) 2015-10-22
PH12015501452A1 (en) 2015-09-21
EP2935221B1 (fr) 2018-02-07
WO2014102818A1 (fr) 2014-07-03
TW201441196A (zh) 2014-11-01
KR20150085535A (ko) 2015-07-23
EP2935221A1 (fr) 2015-10-28
IL239109B (en) 2019-07-31
BR112015014222B1 (pt) 2022-12-06
CL2015001802A1 (es) 2015-10-02
JP6026013B2 (ja) 2016-11-16
US9394300B2 (en) 2016-07-19
AP2015008502A0 (en) 2015-06-30
MY175854A (en) 2020-07-14
UA117122C2 (uk) 2018-06-25
TWI598339B (zh) 2017-09-11
EA028402B1 (ru) 2017-11-30
NZ708605A (en) 2016-07-29
CA2894636A1 (fr) 2014-07-03
CA2894636C (fr) 2018-04-03
TR201802305T4 (tr) 2018-03-21
ES2660288T3 (es) 2018-03-21
SG11201504458XA (en) 2015-07-30
JP2016503052A (ja) 2016-02-01

Similar Documents

Publication Publication Date Title
MA38138A1 (fr) Dérivés inédits de quinolone
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA37405A1 (fr) Composés hétérocyclyle
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA38175A1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA35024B1 (fr) Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA38287A1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA29791B1 (fr) Composes therapeutiques.
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA34760B1 (fr) Composés et leurs utilisation
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA38679B1 (fr) Modulateurs du récepteur de cxcr7